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Lymphoid tissueBackground: Gain-of-function (GOF) mutations affecting the
coiled-coil domain or the DNA-binding domain of signal
transducer and activator of transcription 1 (STAT1) cause
chronic mucocutaneous candidiasis disease. This condition is
characterized by fungal and bacterial infections caused by
impaired generation of TH17 cells; meanwhile, some patients
with chronic mucocutaneous candidiasis disease might also have
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Methods: Because STAT1 is involved in the signaling response to
several cytokines, we studied NK cell functional activities and
STAT1 signaling in 8 patients with STAT1 GOF mutations.
Results: Functional analysis of NK cells shows a significant
impairment of cytolytic and degranulation activities in patients
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Abbreviations used
ChIP: Chromatin immunoprecipitation
CMCD: Chronic mucocutaneous candidiasis disease
E/T: Effector/target
FITC: Fluorescein isothiocyanate
GOF: Gain of function
IFIT1: Interferon-induced protein with tetratricopeptide repeats 1
IL2RA: IL-2 receptor a
MFI: Mean fluorescence intensity
NK: Natural killer
PE: Phycoerythrin
PRL: Prolactin
SOCS: Suppressor of cytokine signaling
STAT: Signal transducer and activator of transcription
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2 TABELLINI ET ALpatients display lower production of IFN-g in response to IL-15
and reduced proliferation after stimulation with IL-2 or IL-15,
suggesting that STAT5 signaling is affected. In addition,
signaling studies demonstrate that the increased
phosphorylation of STAT1 in response to IFN-a is associated
with detectable activation of STAT1 and increased STAT1
binding to the interferon-induced protein with tetratricopeptide
repeats 1 (IFIT1) promoter in response to IL-15, whereas
STAT5 phosphorylation and DNA binding to IL-2 receptor a
(IL2RA) are reduced or not affected in response to the same
cytokine.
Conclusion: These observations suggest that persistent
activation of STAT1 might affect NK cell proliferation and
functional activities. (J Allergy Clin Immunol 2017;nnn:nnn-
nnn.)
Key words: Natural killer cells, cytotoxic activity, IL-15, signal
transducer and activator of transcription 1, signal transducer and
activator of transcription 5, candidiasis
Chronic mucocutaneous candidiasis is a condition character-
ized by impairment of mucosal immunity against Candida albi-
cans. It can be observed in patients with various inborn defects
of the immune response, including disorders caused by mutations
in autoimmune regulator (AIRE), signal transducer and activator
of transcription 3 (STAT3), IL12B, IL12RB1, IL17F, IL17RA, or
RAR-related orphan receptor C (RORC).1-3 In 2011, 2 different
groups reported that monoallelic mutations of STAT1 account
for a large proportion of patients with genetic predisposition to
C albicans infections of the skin, nails, and mucous mem-
branes.4,5 These mutations, causing chronic mucocutaneous
candidiasis disease (CMCD), were shown to be gain-of-
function (GOF) mutations and to affect the coiled-coil or DNA-
binding domain of STAT1. The discovery of these genetic defects
and their pathogenesis have contributed to reveal the role of
TH17 cells in the immune response against Candida species
infections in patients with primary immunodeficiencies.4-10
STAT1 is a transcription factor that regulates many of the
biological effects mediated by type I interferons and other
cytokines in many cell types, including natural killer (NK)
cells.11-13
NK lymphocytes constitute an important cell subset in the
immune response against intracellular pathogens and virally
infected cells.14 Functioning of NK cells is controlled by an array
of different activating and inhibitory receptors15 that, on engage-
ment by specific cell ligands, can either induce or suppress the
process of killing. During early viral infection, STAT1 expression
is dramatically induced and NK cell activity can be influenced by
STAT1 phosphorylation. After type I interferon secretion, NK
cells acquire potent effector functions and secrete immunomodu-
latory cytokines (ie, IL-15) that regulate NK cell expansion.13
Fungal infections constitute themost commonmanifestation of
CMCD, but viral infections, including recurrent mucocutaneous
infections caused by reactivation of varicella-zoster virus and
herpes simplex viruses, debilitating orf infection, or severe inva-
sive infection caused by chicken pox, cytomegalovirus, or EBV
have also been reported.16-21 The broad spectrum of infections
observed in patients with CMCD suggests that susceptibility to
pathogens is not entirely due to the lack of TH17 cells, but other
cell types, particularly NK cells, might play a role in the
pathogenesis of CMCD. To define the role of NK cells in thesusceptibility of patients with CMCD to intracellular pathogens
and viruses, we have investigated NK functional activities and
STAT1 and STAT5 signaling in response to cytokines in these
patients.
Here we report that NK cells from patients with STAT1 GOF
mutations display increased STAT1 phosphorylation in response
to IL-2 and IL-15 but reduced STAT5 activation. This is
associated with impaired NK cell proliferation in response to
IL-2 or IL-15 and reduced IFN-g secretion in response to IL-15.METHODS
Patients
We investigated 8 patients affected by CMCD from 7 families. Some of the
patients had been previously screened for other mutations (ie, AIRE or
CARD9) to rule out other causes of CMCD. In all patients described herein,
we found heterozygous mutations in the coiled-coil or DNA-binding domains
of STAT1: L283M in P1 and his mother P2, L351F in P3, L400V in P6, T837A
in P8,21,22 T385M in P4 and P5,23 and A267V in P7.4 Clinical data from
patients were collected from medical records and are briefly summarized in
Table I. Fungal and bacterial infections were observed in all patients with
CMCD, whereas viral infections were observed in patients P3 and P8.21,22
More detailed information on theMethods used are reported in this article’s
Online Repository at www.jacionline.org.RESULTS
STAT1 phosphorylation in NK cells of patients with
STAT1 GOF mutations
To investigate the mechanism of NK cells activation in
response to cytokines, we explored STAT1 phosphorylation in
response to IFN-a (40,000 U/mL), IL-2 (100 ng/mL), and IL-15
(50 ng/mL) by using flow cytometry in NK cells from both
healthy control subjects and patients with STAT1GOFmutations.
After stimulation, STAT1 phosphorylation was examined by
staining with specific antibodies directed against phosphorylated
tyrosine residues. Analysis of STAT1 signaling in freshly isolated
NK cells (see Fig E1, A, in this article’s Online Repository at
www.jacionline.org) showed higher STAT1 phosphorylation in
response to IFN-a in cells from patients compared with those
from control subjects, suggesting that STAT1 GOF mutations
result in abnormal functioning of STAT1 signaling in NK cells
(Fig 1, A). This observation is in line with previous reports
showing that STAT1 GOF mutations are related to increased
STAT1 phosphorylation.5,18,24,25 Then we investigated STAT1
TABLE I. Genetics and main phenotypical features of 8 patients with STAT1 GOF mutations
P1 P2 P3 P4 P5 P6 P7 P8
Mutation
(cDNA)
c.(847T>A) c.(847T>A) c.(1441G>T) c.(1542C>T) c.(1542C>T) c.(1198C>G) c.(801T>A) c.G372C
Mutation
(amino acids)
L283M L283M L351F T385M T385M L400V A267V T387A
Affected
domain
CCD CCD DBD DBD DBD DBD CCD DBD
Sex Male Female Male Male Male Female Female Male
Age (y) 11 45 33 15 10 7 14 18
Clinical onset 1 year 1 year 6 months 5 years 2 months 2 years 6 months 7 years
Manifestations
of CMC
Oral cavity,
skin, nails
Oral cavity,
nails
Oral cavity,
esophagus
Oral cavity Oral cavity,
esophagus
Oral cavity,
skin, nails
Oral cavity,
genital
mucosa
Oral cavity,
nails,
esophagus
Infections URTI,
pneumonia
URTI,
pneumonia,
skin abscess
URTI, pneumonia,
otitis media,
skin abscess,
cryptococcal
adenitis,
leishmaniasis,
skin HPV,
recurrent
mollusca
URTI,
recurrent
pneumonia
URTI,
Pneumocystis
pneumonia,
otitis media,
sepsis
URTI,
pneumonia,
otitis media
URTI,
pneumonia
Skin abscesses,
periodontitis,
suppurative
eyelid
infection,
mucocutaneous
HSV infection,
severe chicken
pox
Inflammation None Reflux
esophagitis,
recurrent fever,
chronic lung
disease,
bronchiectasis
Recurrent fever,
chronic lung
disease,
bronchiectasis
Bronchiectasis,
anemia
GERD Bronchiectasis,
anemia
None None
Endocrinopathy Hypothyroidism None Hypothyroidism None None None None None
Autoimmunity None None Lupus-like skin
lesion, ANA
and dsDNA
antibody positivity
ANA
positivity,
vitiligo
None None None None
Lymphopenia No Yes Yes 1/2 1/2 No 1/2 No
ANA, Antinuclear antibody; CCD, coiled-coil domain; CMC, chronic mucocutaneous candidiasis; DBD, DNA-binding domain; dsDNA, double-strand DNA;
GERD, gastroesophageal reflux disease; HPV, human papilloma virus; HSV, Herpes simplex virus; URTI, upper respiratory tract infections.
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IL-15.We observed that phosphorylated STAT1 (p-STAT1) levels
increased in response to both IL-2 and IL-15 in NK cells from
patients with STAT1GOFmutations, whereas a remarkably lower
phosphorylation in response to the same cytokines was detected
in healthy control subjects (Fig 1, B-E; P < .05). In addition,
time-course analysis of STAT1 phosphorylation in response to
IFN-a at 15, 30, 60, 90, 120, and 180 minutes in NK and T cells
showed a slower kinetic in protein dephosphorylation in
patients with STAT1 GOF mutations compared with control
subjects (see Fig E1, B-D). This observation is in accordance
with previous studies showing a characteristic delay of STAT1
dephosphorylation.5,18,24,25
Moreover, we investigated STAT1 protein levels in primary
resting NK and T cells from patients with STAT1GOF mutations.
Surprisingly, flow cytometric analysis of STAT1 protein showed a
3-fold increase in STAT1 protein levels in resting NK and T cells
from patients compared with protein levels detected in cells of
healthy control subjects (Fig 1, F, and see Fig E1, E).
NK cells were isolated from PBMCs of patients with STAT1
GOF mutations or from healthy control subjects by using
magnetic beads and cultured with IL-2, as described in the
Methods section, to performWestern blot experiments. However,
we were unable to obtain long-term NK cultures from the
majority of patients, with the exception of patient P7, becauseof reduced proliferation of NK cells and prevalent contamination
of T cells, suggesting an abnormal response of this cell type to
IL-2. Western blot analysis of STAT1 in IL-2–activated NK cells
from patient P7 showed that STAT1 protein levels were increased
in the cells from this subject compared with cells from a healthy
donor (see Fig E1, F).
Furthermore, we performed Western blot analysis of STAT1
phosphorylation in response to IFN-a, IL-2, IL-15, or IL-21 in
NK cell cultures obtained from patient P7 and a control subject.
After withdrawal of IL-2 for 16 hours, IFN-a induced higher
levels of p-STAT1 in cells from patient P7 compared with those in
cells from a healthy control subject. In the same patient increased
STAT1 phosphorylation in response to IL-2 and IL-15 was also
observed, whereas aweaker response to the cytokinewas detected
in cells from the control subject only after prolonged exposure of
the membrane (Fig 1,G andH). Analysis of STAT1 phosphoryla-
tion in response to IL-21 did not reveal STAT1 activation in either
control cells or cells from the patient.NK functional activity and phenotype in patients
with STAT1 GOF mutations
To define the functional properties of NK cells derived from 8
patients with STAT1 GOF mutations, we investigated NK cyto-
lytic activity in freshly isolated PBMCs from patients and control
FIG 1. STAT1 GOF mutations in patients with CMCD are associated with increased STAT1 activation.
A-C, NK cells derived from 5 patients with STAT1 GOF mutations (P3, P5, P6, P7, and P8) and 6 healthy
control subjects were stimulated with IFN-a (Fig 1, A), IL-2 (Fig 1, B), or IL-15 (Fig 1, C) or left unstimulated.
Cells were stained with anti-pY701 STAT1 and analyzed by using flow cytometry after gating CD561CD32
cells. The extent of p-STAT1 intensity (MFI) of a representative patient is shown. D and E, STAT1 activation
in NK cells derived from patients (squares) and healthy donors (circles) after stimulation with IL-2 (Fig 1, D)
or IL-15 (Fig 1, E). Mann-Whitney U test statistical analysis shows a significant difference in the extent of
p-STAT1 expression between patients with STAT1 GOF mutations and control subjects (P < .05). F, NK cells
from 7 patients with CMCD (P1, P2, P3, P4, P5, P7, and P8) and healthy control subjects were stained with
anti-STAT1 and analyzed by means of flow cytometry after gating CD561CD32 cells. The extent of STAT1
intensity is expressed as MFI. Mann-Whitney U test statistical analysis shows a significant difference in
the extent of STAT1 expression between patients with STAT1 GOF mutations (open circles) and control
subjects (triangles; P < .05). Data are presented as medians 6 interquartile ranges. G and H, IL-2–activated
NK cells from a healthy control subject (HD) and patient P7 were stimulated with IFN-a, IL-2, IL-15, IL-21, or
medium alone after IL-2 deprivation for 16 hours. STAT1 phosphorylation was evaluated by means of
Western blotting with an anti–Tyr-701 p-STAT1 mAb. Actin expression was determined to measure protein
loading. Long (Fig 1, H) or short (Fig 1, G) film exposures are shown.
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FIG 2. Impaired NK cell cytotoxicity in patients with STAT1GOFmutations.A and B, Freshly isolated PBMCs
derived from 3 control subjects (triangles) and 3 patients (circles) were incubated overnight, either without
(Fig 2, A) or with (Fig 2, B) IL-2, and tested against the K562 target cell line at different E/T ratios. Data from
the control group show means 6 SDs of 3 replicates. Asterisks indicate a significant difference between
patients with STAT1 GOF mutations and healthy subjects (P < .05). C and D, Degranulation assay (as
measured based on CD107a expression) of freshly isolated CD561CD32 gated NK cells derived from 8
patients with STAT1 GOF mutations (squares) and 10 healthy donors (HD; circles) after stimulation with
the human K562 cell line. PBMCs were incubated overnight without (Fig 2, C) or with (Fig 2, D) IL-2.
Mann-Whitney U test statistical analysis shows a significant difference in the extent of CD107a expression
between patients with STAT1 GOF mutations and control subjects in IL-2–stimulated samples (P < .05).
Results are presented as means 6 SDs.
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healthy subjects by using a chromium release assay. In these ex-
periments we observed a significant reduction in the extent of
cytolytic activity of cells from patients compared with healthy
control subjects (Fig 2, A and B). However, because variability
in the number of NK cells can account for impairment of NK
cell cytotoxicity, we investigated NK cell-surface degranulation
by using flow cytometry after cell culturewith the NK cell suscep-
tible erythroleukemia K562 cell line. We observed that the
degranulation activity of IL-2–activated NK cells was signifi-
cantly lower in patients with STAT1 GOF mutations compared
with that of NK cells from healthy subjects (P < .05; Fig 2, C
andD). In contrast, intracytoplasmic perforin content was normal
in the patients’ NK cells (see Fig E2, A, in this article’s Online Re-
pository at www.jacionline.org).
We analyzed NK cell subsets on the basis of CD56 and CD16
expression and the pattern of activating and inhibitory receptors in
both STAT1-mutated patients and healthy donors. CD57 expression
was decreased on CD56dull NK cells in 3 of 9 patients with STAT1
GOF mutations, whereas killer cell immunoglobulin-like receptor
(KIR) and NKG2A molecules were expressed at normal levels.
Both CD56bright and CD56dull subsets of NK cells showed normal
expression of NKG2D, the activating NK receptors NKp46 andNKp30, and the coreceptors 2B4, NTB-A, and NKp80.26 Likewise,
the expression profile of the chemokine receptors CXCR1 and
CCR7 of the 2 CD56 subsets were normal (see Fig E2, A and B).STAT5 phosphorylation in NK cells of patients with
STAT1 GOF mutations
Because STAT5 mediates the activation of many functional
activities of NK cells, we investigated STAT5 phosphorylation of
IL-2–activated NK cells in response to IL-2 or IL-15 using flow
cytometry.We observed reduced p-STAT5 levels in NK cells from
patients with STAT1 GOF mutations in response to both IL-2 and
IL-15 compared with healthy control cells (Fig 3, A-D; P < .05).
STAT5 protein expression in NK cells, as measured by using flow
cytometry, was similar in patients (Fig 3, F and G) and healthy
control subjects (Fig 3, E). In addition, Western blot analysis of
STAT5 expression on NK cell cultures derived from patient P7
and from a healthy donor showed similar levels of STAT5
expression in cells from a control subject and from a patient
with a STAT1 GOF mutation (Fig 3, H).
Then we investigated STAT5 phosphorylation by means of
Western blotting in response to IFN-a, IL-2, IL-15, or IL-21 in
NK cell cultures from patient P7 or a control subject. In NK cells
FIG 3. STAT1 GOF mutations are associated with reduced STAT5 activation. A and B, NK cells from 5
patients with STAT1 GOF mutations (P3, P5, P6, P7, and P8) and 6 healthy control subjects were stimulated
with IL-2 (Fig 3, A) or IL-15 (Fig 3, B) or left unstimulated. Cells were stained with anti-pY694 STAT5 and
analyzed by means of flow cytometry after gating CD561CD32 cells. A representative case is shown. The
extent of p-STAT5 expression is calculated MFI. C and D, STAT5 activation in NK cells derived from patients
with STAT1 GOF mutations (squares) and healthy donors (circles) after stimulation with IL-2 (Fig 3, C) or
IL-15 (Fig 3, D). Mann-Whitney U test statistical analysis shows a significant difference in the extent of
p-STAT5 expression between patients with STAT1 GOF mutations and control subjects (P < .05). Data are
presented as means 6 SDs. E-G, NK cells derived from patients P4 (Fig 3, F) and P7 (Fig 3, G) and a healthy
control subject (Fig 3, E) were stained with anti-STAT5 and analyzed bymeans of flow cytometry after gating
CD561CD32 cells. STAT5 levels are presented as MFI. H and I, Western blotting analysis of STAT5
expression was carried out on IL-2–activated NK cells derived from a healthy control subject (HD) and
from patient P7 (Fig 3, H). After IL-2 deprivation for 16 hours, IL-2–activated NK cells derived from a healthy
control subject (HD) and from patient P7 were stimulated with IFN-a, IL-2, IL-15, IL-21, or medium alone (Fig
3, I). STAT5 phosphorylation was investigated by means of Western blotting with an anti–Tyr-694 p-STAT5
mAb. Analysis of actin expression was determined to measure protein loading.
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FIG 4. Abnormal STAT1 and STAT5 DNA-binding activity in IL-15–stimulated NK cells. IL-2–activated NK
cells derived from a healthy control subject (HD) and patient P7 after IL-2 deprivation for 16 hours were
stimulated with IL-15 (50 ng/mL) for 45 minutes or left unstimulated. ChIP assay was then performed
with STAT1 (A) and STAT5 (B) antibodies; coimmunoprecipitated DNA samples were amplified by IL2RA,
IFIT1, and PRL promoter–specific primers. Data are expressed as the percentage of total input. Bars
represent SEs calculated from triplicate quantitative PCR reactions. A representative experiment of 2
performed is shown. Asterisks indicate a significant increase in STAT1 or STAT5 recruitment exerted by
IL-15 stimulation: *P < .05, nonparametric Mann-Whitney U test. Statistical analysis was performed directly
on cycle threshold values obtained from triplicate quantitative PCR reactions.
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levels of p-STAT5 induction in response to IL-2 or IL-15,
although no STAT5 phosphorylation was detected in response
to IFN-a or IL-21 (Fig 3, I). In addition, image densitometry anal-
ysis showed that STAT5 phosphorylation was approximately 50%
lower in NK cells from the patient compared with that in cells
from control subjects.
Taken together, these results suggest that the increased STAT1
phosphorylation in response to IL-2 or to IL-15 might affect
STAT5 activation in NK cells of patients with STAT1 GOF
mutations.Abnormal STAT1 and STAT5 DNA binding activity
in NK cells of patients with STAT1 GOF mutations
To evaluate the direct binding of STAT1 and STAT5 to specific
genomic regions containing the canonical ISRE binding site or
the STAT5 binding motif, such as the interferon-induced protein
with tetratricopeptide repeats 1 (IFIT1) and the IL-2 receptor a
(IL2RA) promoters,27,28 we performed the chromatin
immunoprecipitation (ChIP) assay in NK cells from patient 7
and from a control subject (Fig 4). We detected STAT1 binding
to the IFIT1 promoter in resting NK cells from the patient,
probably because of the presence of constitutive activation of
STAT1 in these cells (Fig 4, A). Moreover, IL-15 stimulation of
NK cells from patients induced a stronger recruitment of
STAT1 to the IFIT1 and IL2RA promoters compared with NK
cells from a healthy donor (Fig 4, A). Conversely, STAT5 binding
to IL2RA, a gene strictly dependent on STAT5, was increased by
IL-15 stimulation only in NK cells from the healthy donor but not
in the patient’s cells (Fig 4, B). This is in accordance with the
observation that low levels of STAT5 phosphorylation are
detected in IL-15–stimulated NK cells from patients (Fig 3).
Evidence of increased STAT1 activation in response to IL-2 or
IL-15 and decreased functionality of STAT5 suggest that
abnormal STAT1 signaling might secondarily affect the
STAT5-mediated response of NK cells to IL-15 and to IL-2 in
patients with STAT1 GOF mutations.Gene expression in NK cells of patients with STAT1
GOF mutations
To address the effects of STAT1 GOF mutations on gene
expression, we performed real-time PCR experiments in NK cells
activated with IL-2 for both patient P7 and a healthy control
subject. Cells were cultured without IL-2 for 16 hours and then
stimulated with IL-2 (100 ng/mL) or IL-15 (50 ng/mL) for
24 hours before analysis of STAT1, IL2RA, suppressor of cytokine
signaling 3 (SOCS3), IFNG, and SOCS1 mRNA expression
(Fig 5). We observed that STAT1 mRNA levels were already
increased in unstimulated cells of the patient compared with those
of the healthy control subject. This observation might account for
the increased STAT1 protein levels in NK cells from the same
patient. Moreover, stimulation of NK cells with IL-2 and IL-15
induced a further increase in mRNA expression in the patient
compared with that seen in the control subject (Fig 5, A). Because
patients’ cells show a decrease in STAT5 phosphorylation after
stimulation with IL-2 and IL-15, we evaluated IL2RA mRNA
expression. After treatment with IL-2 or IL-15, we observed a
greater increase in IL2RA mRNA expression in cells from the
patient compared with cells from the control subject (Fig 5, B).
Likewise, IL-2 and IL-15 stimulation of NK cells resulted in
SOCS3 mRNA upregulation in the patient but not in the control
subject (Fig 5, C). Conversely, stimulation with IL-15 showed a
marked increase in IFNG and SOCS1 mRNA expression in
normal control cells, whereas the increase in the patient’s cells
was significantly lower (Fig 5, D and E).NK cell proliferation and IFN-g production
Activated NK cells release cytokines that can modulate various
effector functions of the immune system. To evaluate the
biological response of freshly isolated NK cells of patients with
STAT1 GOF mutations to IL-15 and IL-12 stimulation, we
analyzed IFN-g production after culture with IL-15 or with
IL-12 and IL-18. We observed that IFN-g production in response
to IL-15 was significantly reduced in NK cells from patients with
STAT1GOFmutations compared with those from healthy control
FIG 5. Abnormal gene response in NK cells of a patient with STAT1 GOF mutations to IL-15. IL-2–activated
NK cells from patient P7 and a healthy donor (HD) were stimulated after IL-2 deprivation for 16 hours with
IL-2 (100 ng/mL) or IL-15 (50 ng/mL) or left unstimulated (2) for 24 hours. Relative expression of STAT1
(A), IL-2RA (B), SOCS3 (C), IFNG (D), and SOCS1 (E)mRNAs was measured by using real-time PCR. Target
gene expression was normalized with respect to expression of the housekeeping gene GAPDH and
presented as the n-fold increase ofmRNA expression over unstimulated cells from a healthy control subject.
The experiment shown is representative of 3 independent experiments. Data are presented as
means 6 SDs. Asterisks indicate a significant difference of mRNA levels between the patient and a control
subject (P < .05).
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IL-12 and IL-18 stimulation was normal, suggesting a selective
defect of the NK response to IL-15 stimulation (Fig 6, B).
As pointed out in the Results section, we were unable to
maintain long-term cultures of IL-2–activated NK cells derived
from patients with STAT1 GOF mutations, suggesting a possible
proliferation defect. Therefore we analyzed expression of the
proliferation marker Ki67 after IL-15 or IL-2 stimulation of
freshly isolated PBMCs for 72 hours. We observed that Ki67
induction in response to IL-15 by CD561/CD32 cells was
significantly lower (P < .05) in cells from patients with
STAT1 GOF mutations compared with control NK cells (Fig 6,
C and D).Then we investigated the NK cell proliferative response to IL-2
or IL-15 in patients P3, P7, and P8 by means of analysis of the
nuclear protein Ki67 expression after short-term cultures with IL-
2 and withdrawal of IL-2 in the last 16 hours before stimulation.
We observed that Ki67 expression was considerably decreased in
NK cells derived from patients P3, P7, and P8 after activation for
48 hours with IL-2 or IL-15 compared with the response of NK
cells derived from a representative healthy donor (Fig 6, E).
However, broad variability was observed in the extent of Ki67
expression, suggesting interindividual variability in the
proliferative response of NK cells. To evaluate a possible role
of apoptosis in the regulation of NK cell homeostasis, we
investigated spontaneous and cytokine-induced apoptosis in NK
FIG 6. Reduced IFN-g production and Ki67 expression by NK cells in patients with STAT1 GOF mutations.
A and B, IFN-g production was measured by means of intracellular staining from freshly isolated CD561/
CD32 NK cells derived from 8 patients with STAT1 GOF mutations (squares) and 10 healthy donors (circles)
after overnight stimulation with IL-15 (Fig 6, A) or IL-12 with IL-18 (Fig 6, B). The extent of production was
measured as the percentage of IFN-g1 cells. Mann-Whitney U test statistical analysis shows a significant
difference in IFN-g production between patients and control subjects in IL-15–stimulated samples
(P < .05). Results are presented as means 6 SDs. C and D, Ki67 expression determined by means of
intracellular staining was measured in CD561/CD32 NK cells in PBMCs freshly isolated from 3 patients
with STAT1 GOF mutations (squares) and 5 healthy donors (circles) after stimulation for 72 hours with
IL-15 (Fig 6, C) or IL-2 (Fig 6, D). The extent of Ki67 production was measured as a percentage of Ki671 cells.
Mann-Whitney U test statistical analysis shows a significant difference in Ki67 expression between patients
and control subjects in IL-15–stimulated samples (P < .05). E, NK cells derived from 3 patients with STAT1
GOF mutations (P3, P7, and P8) and 1 representative healthy donor were kept in culture with IL-2,
maintained for 16 hours in complete medium without IL-2, and then stimulated with IL-2, IL-2, and IL-15
or IL-15 alone. After 48 hours, expression of the intracytoplasmic protein Ki67 was analyzed by using
flow cytometry. The experiment we show herein is representative of 3 experiments that were performed.
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for 48 hours with IL-15 or medium alone, analysis of Annexin V
staining in NK cells showed comparable levels of apoptosis be-
tween patients and control subjects (see Fig E2, C). These results
suggest that NK cells derived from patients with STAT1GOFmu-
tations display an impaired response to cytokines that signal
throughout STAT5, such as IL-2 and IL-15, resulting in abnormal
proliferation and cytokine production.DISCUSSION
Several studies have shown that STAT1 GOF mutations
observed in patients with CMCD result in impaired generation
of TH17 cells and increased risk of fungal and bacterial infections.
In this study we report that patients with STAT1 GOF mutations
display abnormal NK cell function and proliferation.
In patients with primary immunodeficiencies, such as Wiskott-
Aldrich syndrome, dedicator of cytokinesis 8 deficiency, or
Hermansky-Pudlak type 2 syndrome, NK cells display abnormal
functioning of the cytotoxicity machinery, whereas cellular
response to IL-2 or IL-15 is usually normal.29-31 Interestingly,
in these conditions addition of IL-2 restores NK cytotoxicity, sug-
gesting that the cell response to IL-2 was preserved in patients
with these conditions.31,32
In contrast, NK cytolytic activity against the susceptible human
erythroleukemia K562 cell line was reduced in NK cells activated
with IL-2 in patients with STAT1GOFmutations. This is in accor-
dance with a communication by Forbes et al,33 who reported NK
cytotoxicity impairment in patients with STAT1 GOF mutations.
Moreover, the defect of NK cytotoxic activity in patients with
STAT1 GOF mutations was not related to abnormal expression,
functioning, or both of NK receptors or to reduced perforin
expression but to an impaired response of these cells to IL-2 or
IL-15. Indeed, IFN-g production was reduced in NK cells from
patients with STAT1 GOF mutations after stimulation with
IL-15 but was normal in cells activated with IL-12 and IL-18.
This suggests that the NK cytotoxicity defect detected in patients
with STAT1 GOF mutations is probably related to abnormal
response of these cells to the immunomodulatory cytokines
IL-15 and IL-2.
NK cell functions are modulated in vivo by several cytokines,
including IL-15 and IL-2. In particular, IL-15 is the most potent
cytokine involved in the regulation of NK cell homeostasis,
maturation, and activation.34 IL-15 has a fundamental role in
the development of NK cells and in their proliferation and/or
survival in peripheral lymphoid cells. In fact, IL-15 promotes
survival of mature NK cells through upregulation of antiapoptotic
Bcl2 family members.35 In addition, IL-15 controls both NK cell
homeostatic proliferation and NK cell activation after bacterial,
viral, or fungal infections and synergizes with IL-12 and IL-18
to induce IFN-g production by NK cells.36
IL-2 and IL-15 intracellular pathways share several signaling
components, including the Janus kinase 1 and 3 molecules, IL-15
receptor b, the common gc receptors, and the STAT5a and
STAT5b transcription factors. Moreover, the importance of the
STAT5 pathway for IL-15 biological activities on NK cells is also
highlighted by many studies in mice and human subjects. In
particular, there is evidence in STAT5b-deficient and, to lower
extent, STAT5a-deficient animals that the number of NK cells is
reduced37 and that children carrying STAT5b mutations display
severe immunologic dysfunctions characterized by moderatelymphopenia and NK cytolytic activity defect.38,39 Although
STAT5 expression was normal in NK cells from patients with
STAT1 GOF mutations, the extent of STAT5 phosphorylation in
response to IL-2 or IL-15 was significantly reduced, suggesting
that abnormal functioning of the STAT1 pathway might affect
the cellular response of NK cells to these cytokines. In fact, we
have observed in NK cells from a patient with a STAT1 GOF
mutation that lower levels of STAT5 phosphorylation in response
to IL-15 are associated with impaired upregulation of STAT5
binding to IL2RA, a gene strictly dependent on STAT5.Moreover,
IL-15–dependent induction of the IFNG gene was abnormal in
patients with STAT1 GOF mutations, suggesting an interplay
between STAT1 signaling and STAT5-mediated response of NK
cells to IL-15. In particular, the increase of STAT1 binding to
IL2RA promoter that is observed inNK cells after IL-15 activation
might account for upregulation of IL2RA mRNA. An altered
balance between STAT1 and STAT3 was observed in T cells of
patients with STAT1 GOF mutations stimulated with IL-6 and
IL-27, suggesting that analogous mechanisms involving STAT1
and STAT5 might explain the observed IL2RA upregulation in
IL-15–stimulated NK cells of patients with STAT1 GOF
mutation.40
In patients with CMCD, STAT1 GOF mutations are associated
with a characteristic delay of protein dephosphorylation, resulting
in persistent activation of the signaling pathway.5,18,24,25 In our
study the time course analysis of STAT1 phosphorylation in
response to IFN-a has shown a similar pattern in NK cells of
patients with STAT1 GOF mutations. However, we have also
observed that both resting and IL-2–activated NK cells of these
patients display increased STAT1 protein levels and higher
expression of STAT1 mRNA, suggesting that augmented STAT1
protein levels might concur with the increased response of NK
cells to cytokines signaling throughout STAT1. Higher basal
levels of STAT1 protein in NK cells of patients with STAT1
GOF mutations prevent a correct analysis of p-STAT1
dephosphorylation kinetic after IL-15 or IL-2 stimulation. This
experiment could not be performed in primary cells, thereby
requiring a distinct experimental model that will be the object
of a separate study.
Complete STAT1 deficiency is associated with impaired
cytolytic activity of NK cells and reduced functional response
to IL-15.41 Lack of endogenous IL-15 results in reduced accumu-
lation of NK cells in response to type I interferons, thus suggest-
ing that the coordinated activities of IL-15 and interferons is
required to induce NK proliferation during viral infections and
that STAT1-mediated activation of NK cells has a priming effect
on functional response to IL-15. Interestingly, in patients with
STAT1 GOF mutations, IL-15 or IL-2 stimulation of NK cells
induces strong STAT1 phosphorylation, whereas aweak signaling
response to IL-2 or IL-15 is detected in normal NK cells after
prolonged exposure of the membrane. This suggests that GOF
mutations of STAT1 observed in these patients might confer an
increased sensitivity of NK cells to STAT1-mediated signaling
that will secondarily interfere with STAT5-dependent responses
to IL-15 or IL-2. Likewise, in T cells of patients with STAT1
GOF mutations, the increased and prolonged STAT1
phosphorylation is apparently affecting the STAT3-dependent
responses to IL-23 or IL-6 required for induction of IL-17A and
IL-17F. Although signaling mechanisms of these biological
events remain largely speculative, it is likely that persistent
STAT1 phosphorylation induced in response to various cytokines
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ferentiation and functions of Tand NK cells resulting in impaired
generation of TH17 cells and reduced proliferation of NK cells.
Reduced proliferative response of NK cells associated with
lower IFN-g production in response to IL-15 or IL-2 might result
in an increased risk of invasive viral infection in patients with
STAT1GOFmutations. This is in accordancewith the observation
that a significant proportion of patients with CMCD has been
shown to be at risk of viral infections, suggesting that in patients
with certain conditions, the abnormal function of NK cells might
be related to specific clinical manifestations.
In addition, reduced IFN-g production by activated NK cells is
observed in patients with STAT1 GOF mutations, suggesting
that response to intracellular pathogens might also be
affected. Although STAT4, but not STAT1, is essential for
IL-12–dependent NK cell IFN-g production, IL-15 might be
important when IL-12 production is not sufficient to drive
IFN-g secretion, as observed during intracellular parasite
infections or during immunosuppressive treatment. This
observation could explain why some patients with CMCD can
have infections sustained by intracellular pathogens, such as
Cryptococcus, Leishmania, or mycobateria,42 and might be
helpful for the development of novel therapeutic strategies for
these patients.
We thank Alessandro Moretta for providing the mAbs against NK cell
receptors and Silvia Giliani for fruitful discussion and suggestions.
Clinical implications: GOF mutations of STAT1 result in
impaired proliferation, IFN-g production, and cytolytic activity
of NK cells in patients with STAT1 GOF mutations.
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METHODS
mAbs
Characterization of NK cell-surface markers was performed by using the
following mAbs generated in our laboratory (Department of Molecular and
Translational Medicine, University of Brescia) or kindly provided by A.
Moretta (Laboratory of Molecular Immunology, DIMES, University of
Genoa): BAB281 (IgG1, anti-NKp46); AZ20 (IgG1, anti-NKp30); ON72
(IgG1, anti-NKG2D); SUS142 (IgG2b, anti-CD16); C227 (IgG1, anti-CD69);
FS123 (IgG2a, anti-DNAM-1); 11PB6 (IgG1, anti-KIR2DL1/S1); GL183
(IgG1, anti-KIR2DL2/L3/S2); AZ158 (IgG2a, anti-KIR3DL1/S1/L2); Z199
(IgG2b, anti-CD94/NKG2A); and anti-XA147 (IgM, anti-CD57).
The following commercial antibodies were used in this study: anti-CXCR1
(IgG1; Santa Cruz Biotechnologies, Santa Cruz, Calif); anti-NKG2C (IgG2b;
R&D Systems, Minneapolis, Minn); phycoerythrin (PE)2labeled
anti-CD107a; PE-labeled anti2IFN-g (IgG1; BD Biosciences, PharMingen,
Calif); mixture of fluorescein isothiocyanate (FITC)2labeled CD3,
PC5-labeled CD56, FITC-labeled CD14, and FITC-labeled CD20 (Beckman
Coulter, Immunotech, Marseille, France); anti-hCCR7 (IgG2A; R&D
Systems); PE-labeled anti-Perforin (Ancell, Bayport, Minn); anti-human
Ki-67 antigen (IgG1; Dako, Copenhagen, Denmark).
Cell preparations and flow cytometry
PBMCs derived from patients with STAT1 GOF mutations and healthy
donors, who were referred to the local hospital for minor trauma, were
obtained from heparinized blood by means of density gradient centrifugation
over Ficoll (Sigma, St Louis, Mo). PBMCs were resuspended in RPMI 1640
medium supplemented with 2 mmol/L glutamine, 50 mg/mL penicillin,
50 mg/mL streptomycin, and 10% heat-inactivated FCS (Sigma).
NK lymphocytes were isolated from PBMCs by using negative selection
(NK cell isolation Kit; Miltenyi Biotec, Bergisch Gladbach, Germany) and
then cultured on irradiated feeder cells in the presence of 100 U/mL human
IL-2 (Proleukin; Chiron, Emeryville, Calif) and 1.5 ng/mL PHA (GIBCO,
Carlsbad, Calif) to obtain polyclonal NK cell lines.
For flow cytometric analysis, NK cells derived from peripheral blood were
stained with the appropriate primary mAbs and then incubated with
PE-conjugated isotype-specific goat anti-mouse secondary reagent (Southern
Biotechnology, Birmingham, Ala). Cells were subsequently stained with a
mixture of FITC-labeled CD3, PC5-labeled CD56, FITC-labeled CD14, and
FITC-labeled CD20. NK cell analysis by means of flow cytometry was
performed by gating on CD561, CD32, CD142, and CD202 cells. Perforin
expression analysis in NK cells was performed by using purified PE-labeled
anti-perforin mAb after incubation with Cytofix/Cytoperm (BD Biosciences).
Cell acquisition was performed on a FACSCanto flow cytometer, and data
were analyzed by using the FACSDiva software (Becton Dickinson,Mountain
View, Calif).
Real-time PCR
Total RNAwas extracted from IL-2–activated NK cells left unstimulated or
stimulated with IL-2 (100 ng/mL) or IL-15 (100 ng/mL) for 24 hours by using
the RNeasy Mini Kit (Qiagen, Valencia, Calif), according to the
manufacturer’s instructions. For RT-PCR experiments, 1 mg of DNase-
treated total RNA was used to synthesize the first strand of cDNA by using
the ImProm-II Reverse Transcription System (Promega, Madison, Wis). For
the RT-PCR analysis, Assays-on-Demand Products and TaqMan Master Mix
from Applied Biosystems (Foster City, Calif) were used according to the
instruction manual to analyze STAT1, IFNG, IL2RA, SOCS1, SOCS3, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression.
Target gene expression was normalized to expression of the housekeeping
gene GAPDH and presented as n-fold increase over those in the healthy
control subject by using 22DDCT evaluation.
ChIP assays
ChIP experiments were performed, as previously described,E1 with minor
modifications. Briefly, after stimulation with the appropriate cytokine,
polyclonal NK cell lines were fixed by using 1% formaldehyde for 6 minutes,
followed by incubation with 0.125mol/L glycine for another 6 minutes to stop
the cross-linking reaction. After 3 washes with ice-cold PBS, nuclear extracts
were prepared from 3.53 106 cells. Chromatin was then sheared by means of
sonication and immunoprecipitated with 4 mg of anti-STAT1 (sc-346) or 4 mg
of anti-STAT5 (sc-835; Santa Cruz Biotechnology). The precipitation signal
was quantified also at the promoter of prolactin (PRL) to establish background
levels of ChIP experiments. The coimmunoprecipitated material was
subjected to quantitative PCR analysis by using the following promoter-
specific primers (purchased from Life Technologies, Grand Island, NY):
IL2RA forward, 59-TTCCACAGTTCTGAGAAAGGTG-39; IL2RA reverse,
59-CATGGCAAGGGTTTATGAGG-39; IFIT1 forward, 59-GGCAGCAATG
GACTGATGTTC-39; IFIT1 reverse, 59-GGAAACCGAAAGGGGAA
AGTG-39; PRL forward, 59-AGGGAAACGAATGCCTGATT-39; and PRL
reverse, 59-GCAGGAAACACACTTCACCA-39. Data from quantitative
PCR were expressed as the percentage over input DNA and are displayed as
means 6 SEMs.
Western blotting and flow cytometric analysis
After culture in IL-2 (1,200 U/mL)–containing medium, cells were starved
to reduce basal phosphorylation for 16 hours at 378C in RPMI containing 2%
serum. For Western blot analysis, NK cells were left unstimulated or
stimulated with IFN-a (10,000 U/mL for 30 minutes; PeproTech, Rocky
Hill, NJ), IL-2 (100 ng/mL for 12 minutes, PeproTech), IL-15 (50 ng/mL for
12 minutes, PeproTech), and IL-21 (50 ng/mL for 15 minutes, PeproTech).
After stimulation, cells were placed on ice and washed twice with cold PBS.
Proteins were extracted with extraction buffer (RIPA Buffer; Millipore,
Temecula, Calif) containing protease, phosphatase inhibitors (Thermo Scien-
tific, Waltham, Mass), and EDTA (Thermo Scientific) and maintained on ice
for 15 minutes with occasional mixing. Insoluble material was removed by
means of centrifugation at 12,000g for 15minutes at 48C. Protein lysates (5mg
per sample) were subjected to SDS-PAGE separation on 10% BIS-Tris gel
(NuPage; Life Technologies), and proteins were transferred to a
polyvinylidene difluoride membrane (GE Healthcare, Fairfield, Conn) and
immunoblotted with primary antibody anti-pSTAT1–Tyr-701, anti-pSTAT5–
Tyr-694 (both from Cell Signaling Technology, Danvers, Mass), anti-
STAT5, anti-STAT1 (BD Transduction Laboratory), and anti–b-actin or
tubulin (Sigma-Aldrich, St Louis) as a loading control. Detection was carried
out with horseradish peroxidase–conjugate by using the enhanced
chemoluminescence system (Euroclone LITEAblot Extend), according to
the manufacturer’s instructions. All images were captured with the UVP
Biospectrum AC Imaging System. Densitometric analysis was performed
with Gel-Pro Analyzer Software, version 3.2. Actin was used as a loading
control reference. STAT1 and actin expression in NK cells were calculated
by using densitometric analysis; the STAT1/actin expression ratio was
calculated in cells from a patient with STAT1 GOF mutation and a control
subject.
For flow cytometry, cells were left unstimulated or stimulated with IFN-a
(40,000 U/mL for 30 minutes), IL-2 (100 ng/mL for 12 minutes), or IL-15
(50 ng/mL for 12 minutes) and stained simultaneously with an FITC-
conjugated mouse anti-CD3 IgG mAb and an R-Phycoerythrincyanin5.1
(PerCP-Cy5.5)–conjugated mouse anti-CD56 IgG mAb. Cells were fixed and
permeabilized according to the BD protocol (Protocol III) and stained with
PE-conjugated mouse anti-pSTAT1–Tyr-701 and anti-pSTAT5–Tyr-694 IgG
mAbs (BD PharMingen) or isotype-matchedmAb PE (BDBiosciences). Cells
were analyzed by means of flow cytometry after gating CD561CD32 cells
with a FACSCalibur flow cytometer (BD Biosciences) and analyzed by using
FlowJo version 7.5 Software (TreeStar, Ashland, Ore). The extent of STAT1
phosphorylation or STAT5 phosphorylation was calculated as the mean
fluorescence intensity (MFI) after subtracting the MFI level of unstimulated
cells stained with an isotype-matched mAb.
Analysis of NK cell cytotoxicity, degranulation, and
IFN-g production
For the degranulation assay against the erythroleukemia K562 human cell
line, PBMCs derived from patients and healthy donors were incubated
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overnight with or without 100 U/mL h-IL-2 (Proleukin; Chiron) at 378C. Then
samples were coincubated with target cells at an effector/target (E/T) ratio of
1:3 in a final volume of 200mL in round-bottom 96-well plates at 378C and 5%
CO2 for 3 hours in culture medium containing CD107a-PE mAb. After
1 hour of coincubation, GolgiStop (BD Biosciences PharMingen) was
added at a 1:100 dilution. Surface staining was performed by
incubating cells with CD3, CD14, CD20, and CD56 mAbs for 30 minutes at
48C. Then cells were washed and analyzed by using flow cytometry
(FACSCanto; Becton Dickinson). Analysis of NK cells was performed on
CD561CD32CD142CD202 gated cells.
NK cytotoxic activity was investigated in a 4-hour 51Cr release assay, as
previously described,E2 by using 5 3 103 cells/well at a final E/T ratio of
20:1 with unstimulated or IL-2–activated NK cells against K562 cells as a
target.
PBMCs derived from patients and healthy donors were incubated overnight
at 378C with IL-15 (20 ng/mL; PeproTech), IL-12 (20 ng/mL; PeproTech),
and/or IL-18 (100 ng/mL; PeproTech), as specified, to detect intracellular
production of IFN-g. Then cells were washed, fixed, and permeabilized with
Cytofix/Cytoperm kit (BD Bioscience PharMingen). IFN-g production was
detected by using subsequent intracellular staining with anti–IFN-g–PE (BD
Biosciences PharMingen) on gating of CD561CD32CD142CD202 cells. In
the experiments of degranulation and IFN-g expression, the percentage of
positive cells was calculated, subtracting the baseline CD107a or IFN-g
expression in the absence of stimuli (target cells or cytokines).
Analysis of cell proliferation and apoptosis
NK cell proliferation was investigated by intracellularly staining Ki67
protein. After stimulation for 48 hours with IL-2 or IL-15, primary NK cells
were permeabilized with saponin (0.1% in PBS) at 48C for 20 minutes. Then
cells were incubated with anti–Ki-67 mAb (IgG1; mouse anti-human, 1:40
dilution; Dako) for 1 hour at 48C. After washing, a secondary
PE-conjugated isotype-specific goat anti-mouse (Southern Biotechnology)
was incubated for 30 minutes at 48C before washing with PBS and flow
cytometric analysis.
To analyze cell apoptosis, PBMCs derived peripheral blood of patients, and
healthy donors were incubated with and/or without IL-15 (100 ng/mL) for
48 hours. Then PBMCs were resuspended in Apoptosis Binding Buffer (BD
Biosciences) at 1.53 106 cells/mL and incubated with 5mL of PE-conjugated
Annexin V. Analysis of Annexin V binding was performed after gating
CD561CD32 cells. Finally, cells were acquired by using the FACSCanto
(BD Biosciences).
Statistical analysis
All results are shown as means6 SDs. The nonparametric Mann-Whitney
U test was used. P values of less than .05 were considered significant.
Statistical analysis was carried out by using GraphPad Prism Version 5.0
(GraphPad Software, San Diego, Calif).
Study approval
For PBMCs preparation, peripheral blood samples were collected from
patients with STAT1 GOF mutations and healthy donors and stored as
established in the protocols of Spedali Civili (Brescia, Italy), according to
the approval of the local ethics committee. Written informed consent was
obtained for collection and storage of blood samples for genetic analysis
and immunologic studies, for medical data recording from all patients or
from their caregivers in the case of minors, and from healthy control subjects.
REFERENCES
E1. Tamassia N, Castellucci M, Rossato M, Gasperini S, Bosisio D, Giacomelli M,
et al. Uncovering an IL-10-dependent NF-kappa B recruitment to the IL-1ra
promoter that is impaired in STAT3 functionally defective patients. FASEB J
2010;24:1365-75.
E2. Fontana S, Parolini S, Vermi W, Booth S, Gallo F, Donini M, et al. Innate immu-
nity defects in Hermansky-Pudlak type 2 syndrome. Blood 2006;107:4857-64.
J ALLERGY CLIN IMMUNOL
nnn 2017
12.e2 TABELLINI ET AL
FIG E1. A, NK flow cytometric analysis. After lymphocyte gating on the basis of forward and side scatter
(left panel), the NK cell gate was placed on the CD561CD32CD142CD202 subpopulation (right panel).
B, STAT1 phosphorylation kinetics in NK cells from patients with STAT1 GOF mutations. STAT1
phosphorylation levels were assessed at different time points (15, 30, 60, 90, 120, and 180 minutes) in NK
cells from 7 patients (P1, P2, P3, P4, P5, P7, and P8; open circles) and 6 healthy control subjects (triangles)
after IFN-a stimulation (40,000 U/mL) for 30 minutes. Cells were stained with anti-pY701 STAT1 and
analyzed by using flow cytometry after gating CD561CD32 cells. Asterisks indicate a significant difference
in p-STAT1 levels between patients and healthy subjects (P < .05). Data are presented as
means 6 interquartile ranges. C, The extent of p-STAT1 intensity (MFI) of a representative patient and
representative healthy control subject is shown in response to IFN-a at 30 minutes. D, STAT1
phosphorylation kinetic in T cells from patients with STAT1 GOF mutations. STAT1 phosphorylation levels
was assessed at different time points (15, 30, 60, 90, 120, and 180 minutes) in T cells from 7 patients (P1, P2,
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P3, P4, P5, P7, and P8; open circles) and 6 healthy control subjects (triangles) after IFN-a stimulation (40,000
U/mL) for 30 minutes. Cells were stained with anti-pY701 STAT1 and analyzed by means of flow cytometry
after gating CD31 cells. Asterisks indicate a significant difference in p-STAT1 levels between patients with
STAT1 GOF mutations and healthy subjects (P < .05). Data are presented as means 6 interquartile ranges.
E, T cells from 7 patients with STAT1 GOF mutations (P1, P2, P3, P4, P5, P7, and P8) and healthy control
subjects were stained with anti-STAT1 and analyzed by means of flow cytometry after gating CD321 cells.
The extent of STAT1 intensity is expressed as MFI. Mann-Whitney U test statistical analysis shows a
significant difference in the extent of STAT1 expression between patients with STAT1 GOF mutations
(open circles) and control subjects (triangles; P < .05). Data are presented as means 6 interquartile ranges.
F, Western blot analysis of STAT1 expression was carried out on IL-2–activated NK cells derived from a
healthy control subject (HD) and patient P7 after IL-2 deprivation for 16 hours.
=
FIG E2. A, Comparison of NK cell marker expression in patients with STAT1 GOF mutations and 10 healthy
control subjects. Extent of expression is presented as the percentage of positive cells 6 SD. SDs are shown
for values derived from healthy donors and patients with STAT1 GOF mutations. Perforin expression was
evaluated by using intracellular staining. B, Expression of CD56 by NK cells from patients with STAT1 GOF
mutations (gray columns) and healthy donors (HD; black columns). C, Analysis of NK cell apoptosis
evaluated as percentage of Annexin V1 cells after culture with IL-15 or medium alone for 48 hours from
patients with STAT1 GOF mutations (gray columns) or healthy donors (HD; black columns).
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